{{Rsnum
|rsid=1801252
|Gene=ADRB1
|Chromosome=10
|position=114044277
|Orientation=plus
|ReferenceAllele=A
|MissenseAllele=G
|GMAF=0.1717
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ADRB1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 98.4 | 1.6 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}Variation at this SNP, located in the [[ADRB1]] gene, may encode either the amino acid serine or glycine at amino acid position 49 of the corresponding protein, the beta-1 adrenergic receptor (hence why it is frequently called Ser49Gly). This protein is the target of [[beta blocker]] drugs, and so how well the drug works to help lower a patients [[high blood pressure]] depends in part on this SNP. The status of this SNP is often reported together with the status of SNP [[rs1801253]], which encodes an amino acid variant at position 389 of the same (ADRB1) protein.

One of the best known studies of the effects of these 2 separate SNPs on the average efficacy of the beta blocker [[metoprolol]] in lowering blood pressure (BP) can be summarized for patients with the corresponding genotypes as follows {{PMID|12844134}}:

*[[rs1801252(A;A)]] and [[rs1801253(C;C)]] carriers: 15 point drop in BP
*[[rs1801252(A;G)]] and [[rs1801253(C;C)]] carriers:  9 point drop in BP
*[[rs1801252(A;A)]] and [[rs1801253(C;G)]] carriers:  6 point drop in BP
*[[rs1801252(A;G)]] and [[rs1801253(C;G)]] carriers: <1 point drop in BP

[[rs1801252]] may also influence resting heart rate; see below.
{{omim
|desc=RESTING HEART RATE
|id=109630
|rsnum=1801252
|variant=0002
}}
{{PMID|15312808}} - Additionally, [[rs1801252]] may have some influence on [[personality]], with Gly carriers showing increased odds of low or very low extraversion levels in this particular study (OR = 1.69, 95% CI 1.05-2.71).

{{PMID Auto
|PMID=19743955
|Title=Polymorphisms of the beta1-adrenergic receptor gene are associated with essential hypertension in Chinese
}}

{{PharmGKB
|RSID=rs1801252
|Name_s=ADRB1:Ser49Gly (145A>G)
|Gene_s=ADRB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:12844134
|Annotation=Data from a study on forty hypertensive men and women aged 35 to 65 years suggest that this SNP together with rs1801253 in the ADRB1 gene are important determinants of antihypertensive response to metoprolol.
|Drugs=metoprolol
|Drug Classes=
|Diseases=Hypertension
|Curation Level=Curated
|PharmGKB Accession ID=PA162316714
}}

{{PharmGKB
|RSID=rs1801252
|Name_s=ADRB1:49Ser>Gly
|Gene_s=ADRB1
|Feature=Exon/NonSyn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/adrb1/variant.jsp
|Annotation=This variant results in increased agonist-promoted desensitization and has been well studied for impact on cardiovascular disease and drug response.
|Drugs=
|Drug Classes=
|Diseases=Heart Diseases
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145207
}}

{{PharmGKB
|RSID=rs1801252
|Name_s=ADRB1:Ser49Gly (145A>G)
|Gene_s=ADRB1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:18615004
|Annotation=The haplotype defined by the A allele of this SNP and the C allele of rs1801253 is associated with increased mortality risk in hypertensive patients with documented coronary artery disease. This increased risk was observed in patients with one or two copies of the AC haplotype. Significant association of the AC haplotype with mortality risk manifested in patients who were treated with the Ca++ channel blocker verapamil, but not in patients treated with the beta-blocker atenolol. Thus, individuals with the AC haplotype may experience better outcomes from treatment with atenolol vs. treatment with verapamil. No association was observed for nonfatal myocardial infarction or nonfatal stroke.
|Drugs=atenolol; verapamil
|Drug Classes=
|Diseases=Death
|Curation Level=Curated
|PharmGKB Accession ID=PA162167946
}}

{{ClinVar
|rsid=1801252
|Reversed=0
|FwdREF=A
|FwdALT=G
|REF=A
|ALT=G
|RSPOS=115804036
|CHROM=10
|GMAF=0.1722
|dbSNPBuildID=89
|SSR=0
|SAO=1
|VP=0x050178000000150117110100
|GENEINFO=ADRB1:153
|GENE_NAME=ADRB1
|GENE_ID=153
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000010.10:g.115804036A>G
|CLNSRC=OMIM Allelic Variant
|CLNORIGIN=1
|CLNSRCID=109630.0002
|CLNSIG=5
|CLNCUI=C1821417
|CLNDBN=Resting heart rate
|Disease=Resting heart rate
|CLNACC=RCV000019323.26
|Tags=PM;TPA;PMC;SLO;VLD;G5;GNO;KGPhase1;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.8283; 0.1717
|CLNDSDB=MedGen:OMIM:SNOMED_CT
|CLNDSDBID=C1821417:607276:444981005
|COMMON=1
}}

{{PMID Auto
|PMID=16120061
|Title=The functional significance of genetic variation within the beta-adrenoceptor.
|OA=1
}}

{{PMID Auto
|PMID=17512307
|Title=Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations.
|OA=1
}}

{{PMID Auto
|PMID=18534365
|Title=Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease.
|OA=1
}}

{{PMID Auto
|PMID=18936436
|Title=Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994.
|OA=1
}}

{{PMID Auto
|PMID=19842931
|Title=GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
|OA=1
}}

{{PMID Auto
|PMID=20008943
|Title=Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.
|OA=1
}}

{{PMID Auto
|PMID=20676228
|Title=Lone AF - etiologic factors and genetic insights into pathophysiolgy.
|OA=1
}}

{{GET Evidence
|gene=ADRB1
|aa_change=Ser49Gly
|aa_change_short=S49G
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1801252
|overall_frequency_n=1442
|overall_frequency_d=10530
|overall_frequency=0.136942
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=2
|n_articles_annotated=2
|in_omim=Y
|in_pharmgkb=Y
|nblosum100=2
|autoscore=2
|webscore=N
|summary_short=Better outcome from treatment with atenolol vs. verapamil.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}